Back to Directory

AdcoTx

Antibody–drug conjugates for colorectal cancer

AdcoTx is a biotechnology company developing an antibody–drug conjugate targeting LGR5 for colorectal cancer. Its approach combines a tumour-targeting antibody with a therapeutic payload, aiming to deliver treatment to cancer cells selected through biomarker testing. Based on University of Cambridge research, the company is developing its programme for LGR5-high, microsatellite-stable metastatic colorectal cancer following standard therapies, with a focus on targeted drug delivery.